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Chemobrain – A Foggy Brain of Cancer Patients
The first mention of the term chemobrain appeared in the literature 
in response to a steady flow of clinical reports and research articles on 
neurological dysfunctions and so called “foggy brain” in chemotherapy 
treated cancer patients [1,2]. “Foggy brain” more precisely known as a 
cognitive impairment of the brain is a phenomenon with a long history 
in psychiatry and neurology, however its presence in cancer patients 
has not been reported until relatively recently. Cognitive impairment as 
a result of chemotherapy was first mentioned in the 70s but it was not 
until late 80s when it was clearly recognized. Over years more and more 
reports were providing solid evidence for a chemotherapy associated 
cognitive impairment in cancer patients [3,4]. Patients treated with 
chemotherapeutics were often complaining of visual memory lapses 
(impaired or delayed recognition of objects, pictures, shapes), verbal 
difficulties (difficulties with recalling names, concepts, definitions etc) 
and inability to focus on complex and multi-step tasks. The severity 
of the symptoms depends on the patient, ranging from mild, almost 
unnoticeable changes in brain function to severe, highly symptomatic 
neurological dysfunctions impairing patients’ life [5,6]. 
Chemobrain is the most prevalent in a population of cancer 
patients aged 65 years and above. Numerous studies show that the 
risk of cancer treatment related side effects, including chemobrain, 
increases with age. This is due not so much as to patients’ chronological 
age, but rather stems from limited organ reserves, existing 
comorbidities, polypharmacy, nutritional status, emotional disorders 
and socioeconomic status of these patients [7,8].
The etiology of these chemotherapy associated cognitive 
impairments remains unclear. Reports from animal studies on 
chemotherapy associated brain dysfunctions indicate that chemobrain 
might be a results of a number of intertwined molecular and genetic 
factors such as: increased permeability of blood – brain barrier (BBB), 
altered activity of plasma membrane pumps within central nervous 
system (CNS), DNA damage, telomere shortening, dysfunction of 
cytokine secretion, impaired neuronal regeneration and oxidative 
stress [9,10]. Some studies also indicate that chemobrain might result 
from a combination of vascular (vascular lesions, anemia) and immune 
deficiencies (increased inflammation at the injection site, severe 
immune response) as well as altered expression of apo-lipoprotein E 
gene, involved in the development of Alzheimer’s disease [11]. 
Discussion
Recent studies on patients treated with different chemotherapeutics 
shed some light on possible mechanisms of chemotherapy associated 
cognitive impairments. For example, it has been shown that doxorubicin, 
a common drug for a variety of different types of cancer, causes 
oxidative damage to neutrophil mitochondria likely contributing to 
the development of cognitive dysfunctions [9,12]. Furthermore, studies 
on neurotoxicity of 5-fluorouracil, one of the essential medicines listed 
by WHO, revealed that it reduces levels of BDNF (brain - derived 
neurotropic factor) and double-cortin, a protein regulating neuronal 
migration in the brain, leading to the development of chemobrain [13]. 
Fortunately, in majority of cases chemotherapy triggered cognitive 
dysfunctions are not permanent, disappearing within weeks at best and 
months at worst after the treatment. 
So far, no effective prevention method against chemobrain is 
available, however over years several successful pharmacological 
and non-pharmacological medical interventions aimed at treating 
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chemotherapy associated cognitive dysfunctions have been made. The 
most common pharmacological interventions involves administration 
of psychostimulant drugs such as methylphenidate, used in Attention 
Deficit Hyperactivity Disorder (ADHD) treatment while the most 
prevalent non-pharmacological intervention involves cognitive – 
behavioral therapy [6,14]. The therapy aims to identify and comprehend 
patient’s problem in relation to his/her thoughts, emotions and 
behavior focusing on “here and now”, not dwelling with the past [15]. 
Blood-brain barrier as a likely factor in the chemobrain 
development 
The concept of blood-brain barrier (BBB) was first introduced by 
a nineteenth century German neurologist, Max Lewandowsky and 
further developed by Paul Ehrlich, a Noble Prize winner and precursor 
of the use of what we call now modern chemotherapy. Recent studies 
show that BBB might be the most important factor in the pathogenesis 
of chemobrain, either preventing it or contributing to its development 
[16,17] Figure 1. 
BBB is a key cellular boundary protecting brain against unwanted, 
harmful cytostatics from the blood during chemotherapy. Due to its 
physical and biochemical properties, BBB almost uniformly prevents 
chemotherapeutics from entering sensitive brain tissue – a disadvantage 
in brain cancer treatments, but a significant benefit in all other types 
of cancer therapy effectively protecting brain against chemotherapy 
induced neurotoxicity. BBB permeability is determined by the unique 
structure of the capillary endothelium allowing only for transcellular 
diffusion (small molecules, nutrients and fat soluble substances) or 
carrier facilitated active transport of regulatory proteins and hormones. 
In addition to its morphological, brain capillary endothelium acts also 
as a biochemical regulator, actively metabolizing certain regulatory 
molecules such as adrenaline or dopamine as well as some metabolites 
and toxins whose activity would otherwise disrupt homeostasis and 
affect brain function [18,19]. 
Studies show however that BBB, though highly efficient, might 
be prone to damage in some metabolic or autoimmune diseases and 
certain types of metastasizing, cancers making it possible for harmful 
molecules to enter the brain causing neuronal dysfunction and cognitive 
impairment. It might be hypothesized that in case of chemobrain, 
certain neurotoxic chemotherapeutics alter BBB functionality and 
morphology, allowing them to enter CNS and disrupt homeostasis 
affecting neuronal function and contributing to the development of 
chemotherapy associated cognitive impairments [16,17].
Chemobrain: Nature and treatment – A light in a tunnel 
Chemobrain is a set of cognitive dysfunctions of unclear etiology 
and undetermined incidence diagnosed in cancer patients. It is 
considered to be a side effect of chemotherapy however evidence 
suggests that some cancer patients experience cognitive dysfunctions 
prior to the initiation of chemotherapy treatment indicating that other, 
chemotherapy independent, mechanisms might be involved. It is 
possible that observed changes result from a combination of various, 
unrelated factors such as: previous surgery, effects of anesthesia, 
hormonal therapy, menopause, anxiety and depression, chronic fatigue 
syndrome, comorbidities, adverse reactions to drugs used in adjunctive 
therapy paraneoplastic syndromes or genetic predisposition [2]. The 
number of possible contributors to the pathogenesis of chemobrain 
calls for a better, more appropriate name for this condition i.e., cancer 
therapy associated cognitive changes. 
Conclusion and Further Studies
So far, there have been no prospective studies addressing this 
condition. The lack of knowledge, information and appropriate 
diagnostic and monitoring tools is particularly detrimental for an 
elderly patient (>65 years) population, more susceptible to troublesome 
and life quality affecting cognitive dysfunctions. In the absence of 
effective preventive methods, raising awareness and educating patients 
about possible cognitive dysfunctions as a result of chemotherapy 
should be implemented. All cancer patients undergoing treatment 
and experiencing cognitive dysfunctions should be informed about 
the transient nature of the dysfunction and given options of either 
pharmacological or cognitive – behavioral therapy aimed at reducing 
the symptoms. 
Recent studies on cancer medication and drug development 
have tremendously improved methodology and safety resulting in a 
reduced number of side effects and neurotoxicity. With improved drug 
development protocols we may expect better ways of preventing and 
controlling symptoms of chemobrain. 
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